# A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model

> **NCT01241422** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 22 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** JNJ 40929837
- **DRUG:** Placebo
- **DRUG:** Montelukast

## Key facts

- **NCT ID:** NCT01241422
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01241422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01241422, "A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01241422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*